Watch: the CureRays® explainer series
Prefer to read? The full guide below is complete on its own, with tables you can revisit any time.
What is atypical fibroxanthoma?
Atypical fibroxanthoma (AFX) is an uncommon, generally low-grade skin cancer that arises in sun-damaged skin, almost always on the head and neck — the scalp, ears, face, and nose — of older adults, and more often in men. It typically appears as a firm, dome-shaped, reddish or pink nodule that grows over weeks to months and may bleed, crust, or ulcerate, which often prompts a visit to the doctor. Under the microscope its cells can look alarmingly abnormal, yet AFX behaves much more favorably than that appearance suggests: it is considered a superficial, low-grade tumor that very rarely spreads to lymph nodes or distant organs. It is best understood as the well-behaved, skin-confined end of a spectrum that, at its more dangerous extreme, includes a deeper and more aggressive tumor called pleomorphic dermal sarcoma; the distinction depends on how deep the tumor goes and whether it shows aggressive features such as invasion into deeper tissue, growth along nerves or into blood vessels, or death of tumor tissue (necrosis). For true AFX, the outlook is excellent. The cornerstone of treatment is complete surgical removal, and because AFX can extend slightly beyond its visible edge in chronically sun-damaged skin, margin-controlled surgery — especially Mohs surgery — gives the highest cure rates while sparing tissue on cosmetically sensitive areas of the face and scalp. Radiation has a limited but useful role, mainly for tumors that cannot be completely removed, that recur, or that show more aggressive features placing them closer to the pleomorphic dermal sarcoma end of the spectrum.
The main types
Doctors group atypical fibroxanthoma by where it starts and how it behaves:
| Type | What it means, simply |
|---|---|
| Classic atypical fibroxanthoma | The usual superficial, low-grade form — a firm nodule on sun-damaged head-and-neck skin that rarely spreads and is cured by complete removal. |
| Pleomorphic dermal sarcoma (more aggressive relative) | A deeper, higher-risk tumor on the same spectrum that invades beneath the skin and carries a greater chance of recurrence and, occasionally, spread; treated more aggressively, often with surgery plus radiation. |
| Recurrent atypical fibroxanthoma | A tumor that has come back after incomplete removal; managed with wider margin-controlled surgery and sometimes radiation. |
Staging, in plain terms
Because typical atypical fibroxanthoma is a superficial, low-grade tumor that very rarely spreads, it is not given a formal cancer stage the way most cancers are. What matters instead is a careful description of the tumor under the microscope and how completely it can be removed. The single most important judgment the pathologist makes is whether the tumor is truly a skin-confined AFX or whether it has features that place it in the more aggressive pleomorphic dermal sarcoma category — namely invasion into the deeper fat or muscle beneath the skin, growth along nerves or into blood vessels, or areas of tumor-tissue death (necrosis). This distinction is what drives prognosis and treatment: classic AFX has an excellent outlook and is managed by complete removal alone, whereas a tumor with aggressive features is watched and treated more like a soft-tissue sarcoma, with wider surgery, radiation, and sometimes imaging to check for spread. For typical AFX, distant imaging and lymph node procedures are generally unnecessary because spread is so rare. So rather than a stage number, the framework here is depth and microscopic features (to sort AFX from its aggressive relative) combined with complete surgical clearance.
| No routine cancer stage for typical AFX — a low-grade skin tumor managed by complete removal; deeper, higher-risk lesions are assessed like a soft-tissue sarcoma | What it generally means |
|---|---|
| Localized, low-grade (typical AFX) | A superficial tumor confined to the skin; complete margin-controlled removal is almost always curative. |
| Aggressive features (pleomorphic dermal sarcoma) | A deeper tumor invading beneath the skin or showing nerve/vessel involvement or necrosis; treated with wider surgery and often radiation, with closer follow-up. |
| Recurrent | A tumor that has returned after incomplete removal; managed with margin-controlled re-excision and sometimes radiation. |
| Metastatic (very rare) | The unusual situation, almost always from the aggressive relative, where the tumor spreads to nodes or distant sites; treated with a coordinated specialist plan including radiation and systemic therapy. |
The standard of care
Atypical Fibroxanthoma is almost always treated by a team that may include a surgeon, a medical oncologist, and a radiation oncologist, combining therapies for the best result. The usual building blocks are:
Mohs / margin-controlled surgery
The main curative treatment — removing the tumor while checking the edges microscopically gives the highest cure rates and spares tissue on the face, ears, and scalp.
Wide local excision
Removal with a generous margin of healthy tissue when Mohs isn't available, with careful pathology review of the edges.
Radiation therapy
Reserved for tumors that can't be completely removed, that recur, or that show aggressive (pleomorphic dermal sarcoma) features, where it lowers the chance of local recurrence.
Skin surveillance
Regular skin checks of the treated area and the rest of the sun-damaged skin, since these patients are also prone to other skin cancers.
How radiation treatment works
Radiation therapy treats atypical fibroxanthoma by delivering focused energy that damages the DNA inside the tumor cells so they can no longer grow and divide. For typical AFX, the role of radiation is intentionally limited, and understanding why explains how it is used. AFX is a superficial, low-grade tumor that very rarely spreads, and complete surgical removal — especially margin-controlled (Mohs) surgery — cures the great majority of cases, so radiation is not needed for most patients. Radiation earns its place in the more difficult situations. When a tumor cannot be completely removed because of its size or location, focused external-beam radiation can serve as the main treatment to control it; when the surgical edges come back close or involved and further surgery isn't practical, radiation to the surgical area treats any microscopic disease left behind and lowers the chance of recurrence; and for tumors that have come back, radiation is often combined with re-excision. Radiation takes on a larger, more standard role when the pathologist finds that a tumor is not classic AFX but its deeper, more aggressive relative, pleomorphic dermal sarcoma — there, radiation is used much as it is for other soft-tissue sarcomas, given around surgery to treat the wider, deeper extent of disease and reduce local recurrence. Because these tumors are superficial, radiation oncologists often use electron beams or superficial X-rays, which deposit their dose in the skin while sparing the deeper tissue, and shape the field to protect cosmetically and functionally important areas of the head and neck. In nearly every setting the goal is local control — eradicating disease in and around the original site — rather than treating the whole body, which fits a cancer that so rarely travels. Used selectively alongside margin-controlled surgery, radiation helps secure durable control for the uncommon tumors that surgery alone cannot fully handle.
The main ways radiation is delivered for atypical fibroxanthoma:
Postoperative (adjuvant) radiation
Radiation to the surgical area after removal when margins are close or involved and re-excision isn't practical, or for the more aggressive pleomorphic dermal sarcoma variant, to treat microscopic disease and reduce recurrence.
Definitive radiation
For a tumor that cannot be removed because of size, location, or a patient's medical condition, focused external-beam radiation can serve as the primary treatment.
Electron-beam / superficial radiation
Because these tumors are superficial, electron beams or superficial X-rays can deliver dose to the skin while sparing the deeper tissue beneath, useful on the scalp and face.
Latest studies shaping care
Care keeps improving — often toward getting the same excellent results with less burden on patients. A few developments:
Mohs surgery yields very high cure rates: Series of margin-controlled (Mohs) surgery for atypical fibroxanthoma report local recurrence rates of only a few percent — lower than standard excision — confirming that complete clearance is the key to cure while sparing head-and-neck tissue.[1]
AFX Mohs surgery outcome studies
Distinguishing AFX from pleomorphic dermal sarcoma matters: Pathology studies emphasize that depth of invasion, nerve or vessel involvement, and necrosis separate low-risk AFX from the more aggressive pleomorphic dermal sarcoma, which carries a higher recurrence and small metastatic risk and warrants more aggressive treatment.[2]
AFX versus pleomorphic dermal sarcoma pathology series
Radiation helps difficult and aggressive cases: Reports show radiation lowers local recurrence for AFX with positive margins, for recurrent tumors, and for the pleomorphic dermal sarcoma variant, supporting its selective use when surgery alone is insufficient.[3]
Radiotherapy in AFX and pleomorphic dermal sarcoma
Common questions
The pathology report sounds scary — is atypical fibroxanthoma dangerous? Its cells can look very abnormal under the microscope, but classic AFX behaves much more gently than that appearance suggests. It is a superficial, low-grade skin cancer that very rarely spreads to lymph nodes or distant organs, and complete removal cures the great majority of cases. The main thing to confirm is that the tumor is true AFX and not its deeper, more aggressive relative, pleomorphic dermal sarcoma.
What's the difference between AFX and pleomorphic dermal sarcoma? They sit on the same spectrum. Atypical fibroxanthoma is confined to the skin and is low-risk. Pleomorphic dermal sarcoma is essentially the same kind of tumor but deeper and more aggressive — it invades the fat or muscle beneath the skin or shows growth along nerves or vessels or tissue death — and carries a higher chance of coming back and a small chance of spreading. The deeper tumor is treated more aggressively, often with surgery plus radiation.
When is radiation needed? Most AFX is cured by margin-controlled surgery alone. Radiation is reserved for tumors that can't be completely removed, that come back, or that turn out to be the more aggressive pleomorphic dermal sarcoma. Because these tumors are superficial, radiation can often be delivered with electron beams that treat the skin while sparing the deeper tissue underneath.
References
Numbered sources for the studies cited above. Links open the primary publication on PubMed or the publisher’s site.